Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q1 FY2027 Earnings Presentation
11 slides from Angiodynamics's earnings presentation, Oct 8, 2026
Slide 1: First Quarter FY 2027 Earnings Results
First Quarter FY 2027Earnings Results October 8, 2026
Slide 2: Forward looking statements
Forward looking statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations
Slide 3: Leadership Transition
3 Leadership Transition Eric Honroth named President and Chief Executive Officer, succeeding Jim Clemmer Eric Honroth appointed President and Chief Executive Officer and a member of the Board of Directors, effective November 2, 2026, succeeding Jim Clemmer Follows a comprehensive Board-led search pr
Slide 4: Key Takeaways
4 Q1 FY 2027 Key Takeaways Continued commercial and operational execution drives AngioDynamics’ accelerated and profitable growth. Total +6.9% YoY Revenue Growth Med Tech +13.2% Med Device +1.4% Auryon +14.7% Med Tech YoY Revenue Growth Mech Thrombectomy 6.7% NanoKnife Probes +24.1% Focus on Profita
Slide 5: Financial Snapshot
5 Q1 FY 2027 Financial Snapshot +1.4% Growth +13.2% Growth Segment Revenue Contribution Segment Gross Margin 52.7% 66.2% Med Device Med Tech
Slide 6: Demonstrated Med Tech Growth Execution
6 Demonstrated Med Tech Growth Execution 6 Med Tech ~22% of Total Med Tech 6yr CAGR: +24% Med Tech ~47% of Total
Slide 7: MedTech Performance Snapshot
7 Q1 FY 2027 MedTech Performance Snapshot Auryon: Double-digit growth for the 21st straight quarter, driven by our hospital atherectomy shift, customer base expansion, and early international adoption. Mechanical Thrombectomy: Strong demand for AlphaVac and AngioVac, with continued progress on Alpha
Slide 8: Fiscal Year 2027 Guidance supported by balance sheet strength
8 Fiscal Year 2027 Guidancesupported by balance sheet strength *Guidance was reiterated in conjunction with fiscal Q1 FY 2027 earnings call on October 8, 2026 +12 - 15% Med Tech Metric Current Guidance Net Sales $336.0M - $341.0M Med Tech Net Sales Growth +12% - 15% Med Device Net Sales Growth Flat
Slide 9: Appendix
9 Appendix
Slide 10: Reconciliation of Net Loss and Diluted Loss Per Share to Non-GAAP Adjusted Net Loss
10 Reconciliation of Net Loss and Diluted Loss Per Share to Non-GAAP Adjusted Net Loss and Diluted Loss Per Share(in thousands, except per share data) Reconciliation of Net Loss to Adjusted EBITDA (in thousands)
Slide 11: Detail of Acquisition, Restructuring and Other Items, net
11 Detail of “Acquisition, Restructuring and Other Items, net” (in thousands)